(de-news.net) – Niels Halama, a leading tumor immunologist at the German Cancer Research Center, has described mRNA technology as a major breakthrough in the fight against cancer. He highlighted its potential to enable highly personalized vaccines targeting a broad range of malignant cells. If clinical trials succeed and regulatory approvals follow, mRNA-based cancer therapies could be integrated into current treatments within two to three years, initially focusing on malignant melanoma.

Currently, no mRNA-based therapies have been formally approved for oncology use. Clinical implementation remains lengthy and complex. According to reports, existing candidates in Phase 2 trials have yet to reach Phase 3, the critical step for regulatory clearance, highlighting ongoing challenges.

Germany plays a key role in global mRNA vaccine research. The World Health Organization recognizes mRNA technology as a vital, adaptable tool in modern medicine, well-suited for treating diseases resistant to conventional therapies.